Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on March 13, 2020, covering events occurring between March 9, 2020, and March 12, 2020. The Company is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics and Capital Events
- Capital Raise: The Company completed a registered direct offering of 5,037,038 shares of common stock at a price of $1.35 per share.
- Gross Proceeds: Approximately $6.8 million.
- Offering Expenses: The Company agreed to pay H.C. Wainwright & Co., LLC a cash placement fee of 6.5% of the aggregate purchase price, a management fee of 1.0%, $12,900 for clearing expenses, and reimbursement of legal fees and other expenses totaling $25,000.
- Legal Settlement: The Company entered into a Settlement Agreement with Aegis Capital Corporation to resolve a lawsuit regarding a lock-up violation. The Company agreed to pay an undisclosed material amount.
Material Changes and Corporate Actions
- Termination of Underwriting Agreement: As part of the settlement with Aegis Capital, the Company terminated the Underwriting Agreement dated October 30, 2019, including the lock-up provisions, subject to certain exclusions.
- Board Departure: Todd Brady resigned as a director and member of the Audit Committee, effective immediately on March 10, 2020.
- Nasdaq Compliance: The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement, as the closing bid price remained at least $1.00 per share for 10 consecutive business days.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance or financial projections. However, the settlement with Aegis Capital involves an undisclosed material payment, representing a financial contingency. The termination of the lock-up provisions may impact future share issuance restrictions. The Company noted that the descriptions of the Purchase Agreement and Settlement Agreement are qualified by reference to the full text of such documents filed as exhibits.
Investor Verification Checklist
- Verify the exact amount of the "undisclosed material amount" paid to Aegis Capital Corporation in the settlement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and use of proceeds.
- Confirm the impact of the director resignation on the composition and quorum of the Audit Committee.
- Monitor future filings for the detailed terms of the terminated Underwriting Agreement exclusions.